Hepatitis C Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Acute Hepatitis C, Chronic Hepatitis C, Others), By Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others), By Diagnosis ( Liver Biopsy, Blood Tests, Imaging Tests, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 9.32 Billion
CAGR (2026-2031)	5.91%
Fastest Growing Segment	Chronic Hepatitis C
Largest Market	North America
Market Size (2031)	USD 13.15 Billion

Market Overview

The Global Hepatitis C Market will grow from USD 9.32 Billion in 2025 to USD 13.15 Billion by 2031 at a 5.91% CAGR. The Global Hepatitis C Market comprises the production and distribution of diagnostic tests and therapeutic agents, specifically Direct Acting Antivirals, designed to manage and cure hepatitis C viral infections. Market growth is fundamentally driven by the escalating burden of the disease alongside international mandates for viral elimination which foster government funded screening and treatment initiatives. Additionally, the superior efficacy and safety profiles of modern antiviral regimens encourage patient adherence and expand the treatable patient population. According to the World Health Organization, in 2024, it was reported that 50 million people globally were living with chronic hepatitis C, creating a sustained demand for effective medical interventions.

Despite these drivers, the market faces a significant challenge regarding the high cost of advanced therapies which restricts access in developing economies with high price sensitivity. This financial barrier is exacerbated by low diagnosis rates as limited healthcare infrastructure in these regions prevents the identification of asymptomatic carriers. Consequently, a vast portion of the infected population remains untreated, thereby hindering the market from realizing its full growth potential and slowing global elimination efforts.

Key Market Drivers

The implementation of Government-Led Disease Elimination Programs serves as a pivotal driver for the market, as countries execute national strategies to meet international health goals. These comprehensive public health frameworks necessitate the large-scale procurement of diagnostics and treatments, creating a sustained commercial avenue for industry stakeholders. A notable success in this domain is the United Kingdom's approach, which demonstrates the efficacy of state-coordinated efforts in driving market-relevant outcomes. According to the Viral Hepatitis Prevention Board, November 2024, in the 'HCV in England report 2024' analysis, the country's elimination strategy successfully reduced the hepatitis C-related mortality rate to 0.41 per 100,000 population, surpassing the World Health Organization's targets and illustrating the impact of funded interventions.

Complementing these policy initiatives, the Widespread Adoption of Advanced Direct-Acting Antiviral Therapies accelerates market growth by ensuring that diagnosed patients can be rapidly and effectively cured. The high safety and simplified dosing of these modern regimens have significantly improved linkage-to-care metrics, driving higher treatment volumes globally. This trend is exemplified by the high uptake rates seen in supportive healthcare environments. According to the British Liver Trust, April 2025, in the 'Hepatitis C in England 2024' report, 96.1% of diagnosed individuals linked to care initiated treatment, highlighting the robust demand for these curative agents. Despite these advancements, the global burden remains a critical driver of ongoing demand. According to the Centers for Disease Control and Prevention, July 2025, in the 'Global Viral Hepatitis' update, approximately 1 million people were newly infected with hepatitis C globally in the preceding year, underscoring the continued necessity for market-supplied solutions.

Download Free Sample Report

Key Market Challenges

The high acquisition cost of advanced antiviral therapies constitutes a significant restraint on market expansion, particularly within developing economies where healthcare funding is limited. High pricing structures frequently exceed the financial capabilities of public health systems and patients, directly restricting the volume of treatment distribution. This economic barrier prevents the market from capitalizing on the high prevalence of the disease in these regions, resulting in substantial revenue loss and limited market penetration in areas that otherwise hold high demand for intervention.

Furthermore, the lack of accessible healthcare infrastructure exacerbates this issue by hindering the identification of the infected population. When diagnostic capabilities are insufficient, a large proportion of patients remain unaware of their status, preventing them from seeking or receiving necessary therapies. According to the World Health Organization, in 2024, only 36% of people living with hepatitis C globally had been diagnosed. This significant gap in diagnosis effectively reduces the addressable market size, as the majority of potential consumers for therapeutic agents remain unidentified and untreated, directly impeding overall market growth.

Key Market Trends

Decentralization of Care to Community Pharmacies is restructuring service delivery by shifting treatment initiation from centralized hospitals to accessible local drugstores. This trend directly mitigates infrastructure barriers by empowering pharmacists to conduct screening and prescribe direct-acting antivirals, effectively capturing patients who might otherwise drop out of the traditional care cascade. The efficacy of this approach in closing the diagnosis-to-cure gap is substantial; according to the National Institutes of Health, October 2025, in the 'Pharmacist Involvement in Hepatitis C Management' study, pharmacist-led programs achieved a therapy initiation rate of 66.5%, significantly outperforming standard referral pathways. By simplifying the patient journey, this model enhances adherence and expands the addressable market within high-prevalence community settings.

Simultaneously, the Adoption of Digital Test-to-Treat Platforms is expanding market penetration by overcoming geographical isolation through virtual engagement. These integrated telemedicine solutions allow healthcare providers to diagnose patients and prescribe curative regimens remotely, bypassing the need for physical clinic visits in underserved regions. This integration has proven critical for engaging hard-to-reach demographics; according to Oregon Health & Science University, November 2024, in the 'Telehealth plus local peer support boosts treatment success for hepatitis C in rural patients' report, 85% of individuals referred to telehealth services successfully enrolled in treatment, compared to only 12% in the control group receiving standard care. This robust uptake confirms that digital platforms are a vital mechanism for unlocking demand in areas with insufficient medical infrastructure.

Segmental Insights

The Chronic Hepatitis C segment is recognized as the fastest-growing category in the global market, primarily driven by the high rate at which acute infections progress into long-term conditions. This expansion is supported by enhanced screening guidelines from authorities such as the Centers for Disease Control and Prevention, which have significantly increased the identification of asymptomatic carriers. The subsequent rise in patient diagnosis has elevated the demand for direct-acting antivirals that provide effective cures. Consequently, the focus on managing and treating this persistent stage of the virus continues to propel market development.

Regional Insights

North America maintains a dominant position in the global hepatitis C market, supported by advanced healthcare infrastructure and widespread access to direct-acting antiviral therapies. The region benefits from favorable reimbursement policies and government initiatives that enhance patient affordability and treatment adherence. Additionally, the U.S. Food and Drug Administration (FDA) facilitates market growth through the efficient approval of new therapeutic options. High rates of diagnosis and screening further drive demand for effective care. These factors, alongside the strong presence of major pharmaceutical companies, ensure North America remains the primary revenue contributor in the global sector.

Recent Developments

• In June 2025, AbbVie announced that the U.S. Food and Drug Administration had approved a label expansion for its direct-acting antiviral therapy, Mavyret (glecaprevir/pibrentasvir). The regulatory decision cleared the use of the drug for the treatment of acute hepatitis C virus infection in adults and pediatric patients aged three years and older. This approval established the therapy as the first and only oral, eight-week treatment option available for patients with acute HCV, addressing a critical need to treat the infection in its early stages and prevent progression to chronic disease.
• In June 2024, Cepheid received marketing authorization from the U.S. Food and Drug Administration for its Xpert HCV test and GeneXpert Xpress System, marking a significant breakthrough in the diagnostic segment of the market. This approval introduced the first point-of-care test capable of detecting hepatitis C virus RNA directly from a fingerstick blood sample in approximately one hour. The authorization enabled the use of the test in non-traditional healthcare settings, such as urgent care clinics and substance use disorder treatment facilities, facilitating a "test-and-treat" approach that allows patients to be diagnosed and linked to care during a single visit.
• In April 2024, Gilead Sciences announced the extension of its strategic partnership with NHS England and the National HCV Elimination Team to work towards the elimination of hepatitis C in England by 2025. The renewal of this collaboration, which was originally established in 2019, focused on using the company's antiviral treatments to cure patients and identifying undiagnosed individuals within marginalized populations. The initiative involved deploying regional coordinators and data analysts to support drug treatment services and prisons, reinforcing the company's commitment to achieving the World Health Organization's goal of eradicating the viral disease by 2030.
• In April 2024, AbbVie was awarded a three-year contract by the Missouri Department of Social Services to partner on "Project HepCure," a statewide initiative designed to accelerate the elimination of the hepatitis C virus. Under this agreement, the company's pan-genotypic treatment, Mavyret (glecaprevir/pibrentasvir), was made available to all participants enrolled in the state's Medicaid program, MO HealthNet. The collaboration aimed to remove barriers to care by providing the medication at no cost to eligible patients and emphasized the importance of early testing and linkage to treatment to reduce the burden of the disease.

Key Market Players

• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Bayer AG
• Merck & Co., Inc.
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company B

By Type	By Treatment	By Diagnosis	By Route of Administration	By Distribution Channel	By Region
Acute Hepatitis C Chronic Hepatitis C Others	Antiviral Drugs Vaccine Immune Modulator Drugs Surgery Others	Liver Biopsy Blood Tests Imaging Tests Others	Oral Parenteral Others	Hospital Pharmacy Retail Pharmacy Online Pharmacy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Hepatitis C Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hepatitis C Market, By Type:

• Acute Hepatitis C
• Chronic Hepatitis C
• Others

• Hepatitis C Market, By Treatment:

• Antiviral Drugs
• Vaccine
• Immune Modulator Drugs
• Surgery
• Others

• Hepatitis C Market, By Diagnosis:

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Others

• Hepatitis C Market, By Route of Administration:

• Oral
• Parenteral
• Others

• Hepatitis C Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

• Hepatitis C Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE